Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-25T04:17:16.668Z Has data issue: false hasContentIssue false
  • English
  • Français

Adjunctive Treatment for Mood Stabilization of Patients with Bipolar I Disorder Treated with Lamotrigine

Published online by Cambridge University Press:  07 November 2014

Theodore Spaulding ,
Ronald Westlund ,
Christine Thomason ,
Robin White ,
Rebekkah Dann  and
Thomas Thompson
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To describe the effect of supplemental psychotropic medications, specifically anxiolytics with sedative/hypnotics (ASH) combined with lamotrigine (LTG) on stabilization of symptoms in patients with bipolar I disorder.

Method:

Symptomatic patients participating in two LTG maintenance trials were classified post-hoc as those initiating LTG as monotherapy (n=313) or as adjunctive therapy (n=814) and further characterized by supplemental add-on therapies received during an open-label treatment phase. Patients were considered stabilized if they reached a stable dose of LTG monotherapy (100–200 mg/day) and had a Clinical Global Impressions-Severity scale score ≤3 for at least 4 weeks. Stabilization rates were compared across initial- and supplemental-treatment groups.

Results:

Patients who initiated and were maintained on LTG monotherapy were stabilized at a slightly higher rate compared with those taking LTG adjunctive therapy (55% vs 48%; P=.080). Stabilization rates were numerically higher for LTG monotherapy patients who later received only ASH as supplemental medication compared with LTG monotherapy throughout, but this difference was not significant (66% vs 55%; P=.271). Stabilization rates were significantly higher for monotherapy patients who later received ASH alone versus other psychotropic medications (66% vs 28%; P=.001). For patients initiating LTG as adjunctive therapy, adding ASH alone resulted in significantly higher stabilization rates than adding another psychotropic medication (62% vs 33%; P<.001).

Conclusion:

LTG and adjunctive treatment with ASH may be useful in the treatment of acute mood symptoms in patients with bipolar I disorder.

Type
Original Research
Information
CNS Spectrums , Volume 11 , Issue 9 , September 2006 , pp. 711 - 718
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Angst, J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998;50:143–151.Google Scholar
2. Marangell, LB. The importance of subsyndromal symptoms in bipolar disorder. J Clin Psychiatry. 2004;65(suppl 10):24–27.Google Scholar
3. Keitner, GI, Solomon, DA, Ryan, CE, et al. Prodromal and residual symptoms in bipolar I disorder. Compr Psychiatry. 1996;37:362–367.Google Scholar
4. The bipolar spectrum: rational polypharmacys. Bowden, CL, Wilcox, JA, eds. Arlington Heights, Ill, ACCESS Medical Group, Department of Continuing Education: 2005.Google Scholar
5. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 suppl):1–50.Google Scholar
6. Goodwin, GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17:149–173.Google Scholar
7. Calabrese, JR, Kasper, S, Johnson, G, et al. International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry. 2004;65:571–579.Google Scholar
8. Suppes, T, Dennehy, EB, Hirschfeld, RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870–886.Google Scholar
9. Yatham, LN, Kennedy, SH, O'Donovan, C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;(7 suppl 3):5–69.Google Scholar
10. Bowden, CL, Calabrese, JR, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392–400.Google Scholar
11. Calabrese, JR, Bowden, CL, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013–1024.Google Scholar
12. Goodwin, GM, Bowden, CL, Calabrese, JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65:432–441.Google Scholar
13. Guy, W. ECDEU Assessment Manual for Psychopharmacology. rev. Washington, DC: Department of Health, Education and Welfare: 1976.Google Scholar